Michael R Irwin1, Richard Olmstead. 1. Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience, University of California, Los Angeles, CA 90095, USA. mirwin1@ucla.edu
Abstract
OBJECTIVES: To evaluate the effects of a behavioral intervention, Tai Chi Chih (TCC) on circulating markers of inflammation in older adults. DESIGN: A prospective, randomized, controlled trial with allocation to two arms, TCC and health education (HE), 16 weeks of intervention administration, and 9 weeks follow-up. PARTICIPANTS: A total of 83 healthy older adults, aged 59 to 86 years. MEASUREMENTS: The primary endpoint was circulating levels of interleukin 6 (IL-6). Secondary outcomes were circulating levels of C-reactive protein, soluble IL-1 receptor antagonist, soluble IL-6 receptor, soluble intercellular adhesion molecule, and IL-18. Severity of depressive symptoms, sleep quality, and physical activity was also assessed over the treatment trial. RESULTS: Among those older adults with high levels of IL-6 at entry, a trend for a treatment group by time interaction was found (F[1,70] = 3.48, p = 0.07), in which TCC produced a drop of IL-6 levels comparable to those found in TCC and HE subgroups who had low levels of IL-6 at entry (t72's = 0.80, 1.63, p's >0.10), whereas IL-6 in HE remained higher than the TCC and HE subgroups with low entry IL-6 (t72 = 2.47, p = 0.02; t72 = 1.71, p = 0.09). Decreases in depressive symptoms in the two treatment groups correlated with decreases of IL-6 (r = 0.28, p <0.05). None of the other cellular markers of inflammation changed in TCC versus HE. CONCLUSION:TCC can be considered a useful behavioral intervention to reduce circulating levels of IL-6 in older adults who show elevated levels of this inflammatory marker and are at risk for inflammation-related morbidity.
RCT Entities:
OBJECTIVES: To evaluate the effects of a behavioral intervention, Tai Chi Chih (TCC) on circulating markers of inflammation in older adults. DESIGN: A prospective, randomized, controlled trial with allocation to two arms, TCC and health education (HE), 16 weeks of intervention administration, and 9 weeks follow-up. PARTICIPANTS: A total of 83 healthy older adults, aged 59 to 86 years. MEASUREMENTS: The primary endpoint was circulating levels of interleukin 6 (IL-6). Secondary outcomes were circulating levels of C-reactive protein, soluble IL-1 receptor antagonist, soluble IL-6 receptor, soluble intercellular adhesion molecule, and IL-18. Severity of depressive symptoms, sleep quality, and physical activity was also assessed over the treatment trial. RESULTS: Among those older adults with high levels of IL-6 at entry, a trend for a treatment group by time interaction was found (F[1,70] = 3.48, p = 0.07), in which TCC produced a drop of IL-6 levels comparable to those found in TCC and HE subgroups who had low levels of IL-6 at entry (t72's = 0.80, 1.63, p's >0.10), whereas IL-6 in HE remained higher than the TCC and HE subgroups with low entry IL-6 (t72 = 2.47, p = 0.02; t72 = 1.71, p = 0.09). Decreases in depressive symptoms in the two treatment groups correlated with decreases of IL-6 (r = 0.28, p <0.05). None of the other cellular markers of inflammation changed in TCC versus HE. CONCLUSION:TCC can be considered a useful behavioral intervention to reduce circulating levels of IL-6 in older adults who show elevated levels of this inflammatory marker and are at risk for inflammation-related morbidity.
Authors: Helen Lavretsky; Lily L Alstein; Richard E Olmstead; Linda M Ercoli; Marquertie Riparetti-Brown; Natalie St Cyr; Michael R Irwin Journal: Am J Geriatr Psychiatry Date: 2011-10 Impact factor: 4.105
Authors: Lisa K Sprod; Michelle C Janelsins; Oxana G Palesh; Jennifer K Carroll; Charles E Heckler; Luke J Peppone; Supriya G Mohile; Gary R Morrow; Karen M Mustian Journal: J Cancer Surviv Date: 2011-12-10 Impact factor: 4.442
Authors: Michael R Irwin; Richard Olmstead; Carmen Carrillo; Nina Sadeghi; Elizabeth C Breen; Tuff Witarama; Megumi Yokomizo; Helen Lavretsky; Judith E Carroll; Sarosh J Motivala; Richard Bootzin; Perry Nicassio Journal: Sleep Date: 2014-09-01 Impact factor: 5.849